These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 29230702)

  • 1. Quantitative PET Imaging in Drug Development: Estimation of Target Occupancy.
    Naganawa M; Gallezot JD; Rossano S; Carson RE
    Bull Math Biol; 2019 Sep; 81(9):3508-3541. PubMed ID: 29230702
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Likelihood estimation of drug occupancy for brain PET studies.
    Schain M; Zanderigo F; Todd Ogden R
    Neuroimage; 2018 Sep; 178():255-265. PubMed ID: 29753104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Simulation of PET scan timings for receptor occupancy studies of CNS drugs: a simple fixed-time design performed as well as scattered time point designs.
    Lee J; Jeon S; Hong T; Han S; Yim DS
    Eur J Clin Pharmacol; 2015 Nov; 71(11):1333-9. PubMed ID: 26350521
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Translational Model-Informed Dose Selection for a Human Positron Emission Tomography Imaging Study of JNJ-54175446, a P2X7 Receptor Antagonist.
    Xu Y; Miao X; Ravenstijn P; Hijzen A; Schmidt ME; Nandy P; Zhou H
    Clin Transl Sci; 2020 Mar; 13(2):309-317. PubMed ID: 31642608
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modeling of PET data in CNS drug discovery and development.
    Varnäs K; Varrone A; Farde L
    J Pharmacokinet Pharmacodyn; 2013 Jun; 40(3):267-79. PubMed ID: 23660778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Restricted maximum likelihood estimation of PET neuroreceptor occupancy in the absence of a reference region.
    Radua J; Bullich S; Lopez N; Catafau AM
    Med Phys; 2011 May; 38(5):2558-62. PubMed ID: 21776791
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Clinical evaluation of CNS drugs with PET].
    Takano A
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):61-5. PubMed ID: 19562943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Positron emission tomographic imaging in drug discovery.
    Ghosh KK; Padmanabhan P; Yang CT; Ng DCE; Palanivel M; Mishra S; Halldin C; Gulyás B
    Drug Discov Today; 2022 Jan; 27(1):280-291. PubMed ID: 34332093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Significance of imaging biomarkers in exploratory clinical trials].
    Takano H; Suhara T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2009 Apr; 29(2):55-9. PubMed ID: 19562942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Designing drug occupancy studies with PET neuroimaging: Sample size, occupancy ranges and analytical methods.
    Laurell GL; Plavén-Sigray P; Svarer C; Ogden RT; Knudsen GM; Schain M
    Neuroimage; 2022 Nov; 263():119620. PubMed ID: 36087903
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET as a Translational Tool in Drug Development for Neuroscience Compounds.
    Varrone A; Bundgaard C; Bang-Andersen B
    Clin Pharmacol Ther; 2022 Apr; 111(4):774-785. PubMed ID: 35201613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Imaging metabotropic glutamate receptor system: Application of positron emission tomography technology in drug development.
    Xu Y; Li Z
    Med Res Rev; 2019 Sep; 39(5):1892-1922. PubMed ID: 30740744
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Guidelines to PET measurements of the target occupancy in the brain for drug development.
    Takano A; Varrone A; Gulyás B; Salvadori P; Gee A; Windhorst A; Vercouillie J; Bormans G; Lammertsma AA; Halldin C
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2255-2262. PubMed ID: 27514528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Quantification of central substance P receptor occupancy by aprepitant using small animal positron emission tomography.
    Endo T; Saijo T; Haneda E; Maeda J; Tokunaga M; Zhang MR; Kannami A; Asai H; Suzuki M; Suhara T; Higuchi M
    Int J Neuropsychopharmacol; 2014 Oct; 18(2):. PubMed ID: 25609595
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Receptor Occupancy of the κ-Opioid Antagonist LY2456302 Measured with Positron Emission Tomography and the Novel Radiotracer 11C-LY2795050.
    Naganawa M; Dickinson GL; Zheng MQ; Henry S; Vandenhende F; Witcher J; Bell R; Nabulsi N; Lin SF; Ropchan J; Neumeister A; Ranganathan M; Tauscher J; Huang Y; Carson RE
    J Pharmacol Exp Ther; 2016 Feb; 356(2):260-6. PubMed ID: 26628406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PET measurement of receptor occupancy as a tool to guide dose selection in neuropharmacology: are we asking the right questions?
    Barrett JS; McGuire J; Vezina H; Spitsin S; Douglas SD
    J Clin Psychopharmacol; 2013 Dec; 33(6):725-8. PubMed ID: 24100788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The application of positron emission tomography (PET) imaging in CNS drug development.
    Suridjan I; Comley RA; Rabiner EA
    Brain Imaging Behav; 2019 Apr; 13(2):354-365. PubMed ID: 30259405
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What Can Mathematics Do for Drug Development?
    Moore H; Allen R
    Bull Math Biol; 2019 Sep; 81(9):3421-3424. PubMed ID: 31332601
    [No Abstract]   [Full Text] [Related]  

  • 19. Label-free assay for the assessment of nonspecific binding of positron emission tomography tracer candidates.
    Assmus F; Seelig A; Gobbi L; Borroni E; Glaentzlin P; Fischer H
    Eur J Pharm Sci; 2015 Nov; 79():27-35. PubMed ID: 26341407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-clinical characterization of [11C]R05013853 as a novel radiotracer for imaging of the glycine transporter type 1 by positron emission tomography.
    Borroni E; Zhou Y; Ostrowitzki S; Alberati D; Kumar A; Hainzl D; Hartung T; Hilton J; Dannals RF; Wong DF
    Neuroimage; 2013 Jul; 75():291-300. PubMed ID: 22178811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.